New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
07:41 EDTHTWR, THORCorrection: Thoratec attractive on any post-guidance weakness, says Oppenheimer
Oppenheimer reports that Thoratec (THOR) will provide 2013 guidance on February 5, and the firm adds that the company has traditionally been conservative with its first outlook of the year. Oppenheimer thinks the stock may be muted in the near-term but it believes that the shares will have a number of positive catalysts later in the year. It recommends buying the shares on any pullbacks. A previous note incorrectly stated that this note from Oppenheimer was written about HeartWare (HTWR).
News For THOR;HTWR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 4, 2015
16:33 EDTTHORThoratec reports Q2 adjusted EPS 37c, consensus 28c
Reports Q2 revenue $128.69M, consensus $118.00M. Reports worldwide HeartMate pump unit growth 20%.
July 30, 2015
07:19 EDTHTWRHeartWare sold 773 HeartWave HVAD systems globally
Subscribe for More Information
07:19 EDTHTWRHeartWare reports Q2 non-GAAP EPS (47c), consensus (49c)
Reports Q2 revenue $73.6M, consensus $71.87M
July 24, 2015
16:30 EDTTHORStocks end week lower as Apple headlines busy week of earnings
Subscribe for More Information
July 23, 2015
10:00 EDTTHOROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTTHOR, HTWRNorthland sees HeartWare takeover as 'highly unlikely
Northland analyst Suraj Kalia believes the sympathy rally in shares of HeartWare (HTWR) after St. Jude Medical (STJ) announced the acquisition of Thoratec (THOR) could be short lived. HeartWare has already tried to sell itself to larger medical device companies over the past few years, Kalia tells investors in a research note, citing his own field work. He views a buyout of HeartWare at this stage as "highly unlikely" and feels speculation of a $102-$122 per share takeover price is based on "naïve and unsophisticated" analysis. Kalia keeps an Underperform rating on HeartWare with a $60 price target. The maker of implantable heart pumps, following a two-day rally, closed yesterday at $88.21.
07:02 EDTTHORSt. Jude Medical downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
05:25 EDTTHORThoratec downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo downgraded Thoratec (THOR) to Market Perform saying it does not believe the likelihood of another bidder is high enough to warrant an Outperform rating. Yesterday the company announced an agreement to be acquired by St. Jude Medical (STJ) for $63.50 per share.
July 22, 2015
16:27 EDTTHOROn The Fly: Top stock stories for Wednesday
Stocks began the session in negative territory and remained there throughout the day. Uninspiring earnings reports from Apple (AAPL) and Microsoft (MSFT) were enough to push the Nasdaq lower and the rest of the market followed. There was good news on the housing sector, with both existing home sales and a housing market index coming in with good data, but it was not enough to overcome the tech selloff. ECONOMIC EVENTS: In the U.S., the FHFA home price index rose 0.4% to 222.8 in May, as expected. Existing home sales rose 3.2% to a 5.49M rate in June, better than the 0.9% increase that was expected. In Europe, the European Central Bank reportedly raised the cap on Greece's Emergency Liquidity Assistance by EUR900M to EUR90.4B, according to Bloomberg. COMPANY NEWS: Shares of Apple dropped $5.79, or 4.43%, to $124.96 after iPhone shipments in the just completed quarter and the company's sales forecast for the new quarter missed estimates. A number of suppliers to Apple declined in tandem with the tech giant. Skyworks Solutions (SWKS), Qorvo (QRVO) and NXP Semiconductors (NXPI) were among the many semiconductor stocks that slid following Apple's report... Microsoft declined $1.88, or 3.97%, to $45.40 after reporting its Q4 Devices and Consumer revenue declined 13% and its Windows OEM revenue decreased 22% as revenue was impacted by PC market declines following the XP end-of-support refresh cycle. MAJOR MOVERS: Among the notable gainers was Thoratec (THOR), which rose $5.84, or 10.14% to $63.42 after St. Jude Medical (STJ) announced an agreement to acquire the company for $63.50 per share in a transaction valued at $3.4B. Shares of St. Jude, meanwhile, edged down by 4c to $76.67. Also higher following earnings reports were shares of Intuitive Surgical (ISRG) and Chipotle Mexican Grill (CMG), advancing about 8.5% and 7.8%, respectively. Among the noteworthy losers was Caesars Entertainment (CZR), which dropped $3.26, or 40.65%, to $4.76 following reports that a judge ruled the company must face certain creditor lawsuits that could force a bankruptcy. Caesars Acquisition (CACQ) also dipped after the news, falling $1.13, or 14.52%, to $6.65. Also lower was XOMA (XOMA), which plummeted $3.46, or 78.61%, to 94c and saw downgrades at numerous research firms after the company's Phase 3 gevokizumab study did not meet its primary endpoint. INDEXES: The Dow fell 65.60, or 0.37%, to 17,853.69, the Nasdaq lost 36.35, or 0.7%, to 5,171.77, and the S&P 500 declined 5.06, or 0.24%, to 2,114.15.
12:32 EDTTHOROn The Fly: Top stock stories at midday
Stocks on Wall Street were lower at midday as slides in a number of big name tech stocks following their earnings reports dominated the news flow and largely dictated the market's direction. ECONOMIC EVENTS: In the U.S., the FHFA home price index rose 0.4% to 222.8 in May, as expected. Existing home sales rose 3.2% to a 5.49M rate in June, better than the 0.9% increase that was expected. In Europe, the European Central Bank reportedly raised the cap on Greece's Emergency Liquidity Assistance by EUR900M to EUR90.4B, according to Bloomberg. COMPANY NEWS: The tech sector has been weak, headlined of course by a 5% pullback in shares of Apple (AAPL) after iPhone shipments in the just completed quarter and the company's sales forecast for the new quarter missed estimates. Adding to the negative tone in tech stocks, and contributing further to the decline in the Nasdaq, was the 3% drop seen in Microsoft (MSFT) shares after its quarterly report as well as Yahoo's (YHOO) 1% decline after its revenue outlook missed the consensus forecast... Shares of Boeing (BA) and Coca-Cola (KO) fared better than Dow peer Apple after each reported better than expected sales and profits, though neither stock was moving far from where they closed yesterday's trading. MAJOR MOVERS: Among the notable gainers was Thoratec (THOR), which rose 10% after the company agreed to be acquired by St. Jude Medical (STJ) for $3.4 billion in cash, or $63.50 per share. St. Jude shares advanced fractionally after the deal, which had been foreshadowed by media reports yesterday, was announced. Also higher following their earnings reports were Intuitive Surgical (ISRG), which gained 10%, Chipotle Mexican Grill (CMG), which advanced 8% and Whirlpool (WHR), which was up 6%. Among the noteworthy losers were a number of suppliers to Apple that declined in tandem with the tech giant after it reported a sequential drop in iPhone sales. Skyworks Solutions (SWKS), Cirrus Logic (CRUS), Qorvo (QRVO) and NXP Semiconductors (NXPI) were among the many semiconductor stocks that slid following Apple's report. Also sharply lower was antibody-based therapeutics maker XOMA (XOMA), which plunged more than 73% and was downgraded to Neutral at Piper Jaffray after a Phase III trial of its gevokizumab drug in patients with Behcet's disease uveitis did not meet its primary endpoint. INDEXES: Near midday, the Dow was down 82.22, or 0.46%, to 17,837.07, the Nasdaq was down 42.68, or 0.82%, to 5,165.44, and the S&P 500 was down 6.93, or 0.33%, to 2,112.28.
10:15 EDTTHORThoratec downgraded to Market Perform from Outperform at Northland
Subscribe for More Information
10:10 EDTTHORHigh option volume stocks
High option volume stocks: HNT THOR QRVO CYTR CBRL MAS CHKP TUP NXPI VEDL
09:07 EDTTHOROn The Fly: Pre-market Movers
Subscribe for More Information
07:07 EDTTHORThoratec reports Q2 preliminary revenue $128M-$129M, consensus $115.48M
Subscribe for More Information
07:02 EDTTHORSt. Jude Medical sees Thoratec deal accretive to adjusted EPS in 2016
Subscribe for More Information
07:02 EDTTHORSt. Jude Medical to acquire Thoratec for $63.50 per share, deal valued at $3.4B
St. Jude Medical (STJ) and Thoratec (THOR) announced that the Boards of Directors of both companies have unanimously approved a definitive agreement under which St. Jude Medical will acquire all of the outstanding shares of Thoratec for $63.50 per share in a cash transaction valued at approximately $3.4B, net of cash acquired. The all-cash transaction represents a premium of 40.1 percent compared to $45.34, Thoratec's volume-weighted average trading price for the 30 trading day period ending July 17, 2015, and a 35.4 percent premium to the closing price on Thoratec's last unaffected trading date on July 17, 2015 of $46.89. The transaction is expected to be completed in the fourth quarter of 2015. Under the terms of the merger agreement, Thoratec shareholders will receive $63.50 in cash, without interest, for each share of Thoratec common stock they own. The transaction is conditioned upon, among other things, Thoratec shareholder approval, regulatory approvals and other customary closing conditions. The transaction is not conditioned on financing. St. Jude Medical intends to fund the transaction through proceeds from additional bank term loan debt and senior unsecured notes. St. Jude Medical is committed to maintaining a strong investment grade rating. The merger agreement includes a “go-shop” period, during which Thoratec will actively solicit alternative proposals from third parties for the next 30 days continuing through August 20, 2015. The merger agreement provides for Thoratec to pay a termination fee of approximately $30 million to St. Jude Medical if Thoratec terminates the merger agreement in connection with a superior proposal that arose during the go-shop period and a termination fee of approximately $111 million if Thoratec terminates the merger agreement in connection with a superior proposal that arose following the go-shop period. There can be no assurance that this process will result in a superior proposal. Thoratec does not intend to disclose developments with respect to the solicitation process unless and until its Board of Directors has made a decision with respect to any potential superior proposal. This transaction is expected to be accretive to adjusted earnings per share in 2016. St. Jude Medical also expects the combined company to capture revenue and technology synergies following the completion of this transaction. This acquisition positions St. Jude Medical to enter new markets totaling more than $1 billion that are expected to grow approximately 10 percent annually, benefitting St. Jude Medical’s sales growth profile beginning in 2016. Bank of America Merrill Lynch is acting as financial advisor to St. Jude Medical and has also provided fully committed financing. Gibson, Dunn & Crutcher LLP is serving as legal counsel to St. Jude Medical. Guggenheim Securities is acting as financial advisor to Thoratec, and Latham & Watkins LLP is serving as legal counsel. Centerview Partners provided a fairness opinion to the Board of Directors of Thoratec in connection with the transaction.
07:00 EDTTHORSt. Jude Medical to acquire Thoratec for $63.50 per share, deal valued at $3.4B
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use